132 related articles for article (PubMed ID: 22177599)
41. Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes.
Crane L; Anastassiadou M; El Hage S; Stigliani JL; Baziard-Mouysset G; Payard M; Leger JM; Bizot-Espiard JG; Ktorza A; Caignard DH; Renard P
Bioorg Med Chem; 2006 Nov; 14(22):7419-33. PubMed ID: 16889967
[TBL] [Abstract][Full Text] [Related]
42. Syntheses of vanadyl and zinc(II) complexes of 1-hydroxy-4,5,6-substituted 2(1H)-pyrimidinones and their insulin-mimetic activities.
Yamaguchi M; Wakasugi K; Saito R; Adachi Y; Yoshikawa Y; Sakurai H; Katoh A
J Inorg Biochem; 2006 Feb; 100(2):260-9. PubMed ID: 16387366
[TBL] [Abstract][Full Text] [Related]
43. PARP inhibitors: new tools to protect from inflammation.
Giansanti V; Donà F; Tillhon M; Scovassi AI
Biochem Pharmacol; 2010 Dec; 80(12):1869-77. PubMed ID: 20417190
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and preliminary evaluation of selected 2-aryl-5(6)-nitro- 1H-benzimidazole derivatives as potential anticancer agents.
Romero-Castro A; León-Rivera I; Avila-Rojas LC; Navarrete-Vázquez G; Nieto-Rodríguez A
Arch Pharm Res; 2011 Feb; 34(2):181-9. PubMed ID: 21380799
[TBL] [Abstract][Full Text] [Related]
45. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Menear KA; Adcock C; Boulter R; Cockcroft XL; Copsey L; Cranston A; Dillon KJ; Drzewiecki J; Garman S; Gomez S; Javaid H; Kerrigan F; Knights C; Lau A; Loh VM; Matthews IT; Moore S; O'Connor MJ; Smith GC; Martin NM
J Med Chem; 2008 Oct; 51(20):6581-91. PubMed ID: 18800822
[TBL] [Abstract][Full Text] [Related]
46. The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
Liu Y; Lang Y; Patel NK; Ng G; Laufer R; Li SW; Edwards L; Forrest B; Sampson PB; Feher M; Ban F; Awrey DE; Beletskaya I; Mao G; Hodgson R; Plotnikova O; Qiu W; Chirgadze NY; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
J Med Chem; 2015 Apr; 58(8):3366-92. PubMed ID: 25763473
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhibitor.
Lord AM; Mahon MF; Lloyd MD; Threadgill MD
J Med Chem; 2009 Feb; 52(3):868-77. PubMed ID: 19117416
[TBL] [Abstract][Full Text] [Related]
48. Design and synthesis of 1H-indazole-3-carboxamide derivatives as potent and selective PAK1 inhibitors with anti-tumour migration and invasion activities.
Zhang M; Fang X; Wang C; Hua Y; Huang C; Wang M; Zhu L; Wang Z; Gao Y; Zhang T; Liu H; Zhang Y; Lu S; Lu T; Chen Y; Li H
Eur J Med Chem; 2020 Oct; 203():112517. PubMed ID: 32846314
[TBL] [Abstract][Full Text] [Related]
49. Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries.
Ferraris D; Ficco RP; Dain D; Ginski M; Lautar S; Lee-Wisdom K; Liang S; Lin Q; Lu MX; Morgan L; Thomas B; Williams LR; Zhang J; Zhou Y; Kalish VJ
Bioorg Med Chem; 2003 Aug; 11(17):3695-707. PubMed ID: 12901915
[TBL] [Abstract][Full Text] [Related]
50. One-pot tandem Hurtley-retro-Claisen-cyclisation reactions in the synthesis of 3-substituted analogues of 5-aminoisoquinolin-1-one (5-AIQ), a water-soluble inhibitor of PARPs.
Woon EC; Sunderland PT; Paine HA; Lloyd MD; Thompson AS; Threadgill MD
Bioorg Med Chem; 2013 Sep; 21(17):5218-27. PubMed ID: 23849206
[TBL] [Abstract][Full Text] [Related]
51. Recent Advances in Indazole-Containing Derivatives: Synthesis and Biological Perspectives.
Zhang SG; Liang CG; Zhang WH
Molecules; 2018 Oct; 23(11):. PubMed ID: 30373212
[TBL] [Abstract][Full Text] [Related]
52. Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors.
Patel MR; Bhatt A; Steffen JD; Chergui A; Murai J; Pommier Y; Pascal JM; Trombetta LD; Fronczek FR; Talele TT
J Med Chem; 2014 Jul; 57(13):5579-601. PubMed ID: 24922587
[TBL] [Abstract][Full Text] [Related]
53. Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy.
Gu H; Yan W; Yang J; Liu B; Zhao X; Wang H; Xu W; Wang C; Chen Y; Dong Q; Zhu Q; Xu Y; Zou Y
J Med Chem; 2024 Feb; 67(3):1932-1948. PubMed ID: 38059836
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis and biological evaluation of pyridazino[3,4,5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors.
Wang J; Tan H; Sun Q; Ge Z; Wang X; Wang Y; Li R
Bioorg Med Chem Lett; 2015 Jun; 25(11):2340-4. PubMed ID: 25899312
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship.
Chen M; Huang H; Wu K; Liu Y; Jiang L; Li Y; Tang G; Peng J; Cao X
Drug Dev Res; 2022 Feb; 83(1):55-63. PubMed ID: 34151456
[TBL] [Abstract][Full Text] [Related]
56. A novel series of indazole-/indole-based glucagon receptor antagonists.
Lin S; Zhang F; Jiang G; Qureshi SA; Yang X; Chicchi GG; Tota L; Bansal A; Brady E; Trujillo M; Salituro G; Miller C; Tata JR; Zhang BB; Parmee ER
Bioorg Med Chem Lett; 2015 Oct; 25(19):4143-7. PubMed ID: 26303893
[TBL] [Abstract][Full Text] [Related]
57. Synthesis of substituted 1H-indazoles from arynes and hydrazones.
Li P; Wu C; Zhao J; Rogness DC; Shi F
J Org Chem; 2012 Apr; 77(7):3149-58. PubMed ID: 22414117
[TBL] [Abstract][Full Text] [Related]
58. Indazole derivatives and their therapeutic applications: a patent review (2013-2017).
Denya I; Malan SF; Joubert J
Expert Opin Ther Pat; 2018 Jun; 28(6):441-453. PubMed ID: 29718740
[TBL] [Abstract][Full Text] [Related]
59. Lactoperoxidase, an antimicrobial enzyme, is inhibited by some indazoles.
Köksal Z; Alim Z
Drug Chem Toxicol; 2020 Jan; 43(1):22-26. PubMed ID: 30126312
[TBL] [Abstract][Full Text] [Related]
60. Structural requirements of some 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide derivatives as poly (ADP-ribose) polymerase (PARP) for the treatment of cancer: QSAR approach.
Sharma MC
Interdiscip Sci; 2014 Sep; ():. PubMed ID: 25183353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
